These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7507054)

  • 41. Origin and structure of benign prostatic hyperplasia.
    Jones DR; Parkinson MC; Griffiths GJ; Davies RL; Peeling WB
    Br J Urol; 1990 Nov; 66(5):506-8. PubMed ID: 1701106
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia.
    Polnaszek N; Kwabi-Addo B; Wang J; Ittmann M
    Prostate; 2004 Jun; 60(1):18-24. PubMed ID: 15129425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Origin and evolution of benign prostatic enlargement.
    McNeal JE
    Invest Urol; 1978 Jan; 15(4):340-5. PubMed ID: 75197
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of gold nanoparticles treatment on the testosterone-induced benign prostatic hyperplasia in rats.
    Al-Trad B; Aljabali A; Al Zoubi M; Shehab M; Omari S
    Int J Nanomedicine; 2019; 14():3145-3154. PubMed ID: 31118628
    [No Abstract]   [Full Text] [Related]  

  • 45. Metformin inhibits the proliferation of benign prostatic epithelial cells.
    Wang Z; Xiao X; Ge R; Li J; Johnson CW; Rassoulian C; Olumi AF
    PLoS One; 2017; 12(3):e0173335. PubMed ID: 28253329
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of benign prostatic hypertrophy in baboons.
    Karr JP; Kim U; Resko JA; Schneider S; Chai LS; Murphy GP; Sandberg AA
    Urology; 1984 Mar; 23(3):276-89. PubMed ID: 6199881
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond.
    Montironi R; Valli M; Fabris G
    J Clin Pathol; 1996 Apr; 49(4):324-8. PubMed ID: 8655710
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Prostate gland-transition zone lesions. Etiology, growth regulation, growth factors, genetic changes].
    Pavelić J; Zeljko Z
    Lijec Vjesn; 2002; 124(6-7):211-9. PubMed ID: 19658339
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings.
    Schiebler ML; Tomaszewski JE; Bezzi M; Pollack HM; Kressel HY; Cohen EK; Altman HG; Gefter WB; Wein AJ; Axel L
    Radiology; 1989 Jul; 172(1):131-7. PubMed ID: 2472644
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human benign prostatic hyperplasia: a stromal disease? New perspectives by quantitative morphology.
    Rohr HP; Bartsch G
    Urology; 1980 Dec; 16(6):625-33. PubMed ID: 6160671
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ursolic acid reduces prostate size and dihydrotestosterone level in a rat model of benign prostatic hyperplasia.
    Shin IS; Lee MY; Jung DY; Seo CS; Ha HK; Shin HK
    Food Chem Toxicol; 2012 Mar; 50(3-4):884-8. PubMed ID: 22266360
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mesenchymal stem cells and the embryonic reawakening theory of BPH.
    Brennen WN; Isaacs JT
    Nat Rev Urol; 2018 Nov; 15(11):703-715. PubMed ID: 30214054
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relationship between the prostatic tissue components and natural history of benign prostatic hyperplasia.
    Matsuda T; Fujime M; Suda K
    Anal Quant Cytol Histol; 2006 Jun; 28(3):121-4. PubMed ID: 16786720
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epithelial proliferations in prostatic stromal tumors of uncertain malignant potential (STUMP).
    Nagar M; Epstein JI
    Am J Surg Pathol; 2011 Jun; 35(6):898-903. PubMed ID: 21572264
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stereological evaluation of fibronectin in the periurethral region of the transitional zone from normal human prostates compared with benign prostatic hyperplasia.
    Manaia JH; Cardoso GP; Babinski MA
    Int J Clin Exp Pathol; 2015; 8(4):4143-7. PubMed ID: 26097605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Platelet derived growth factor (PDGF), androgens and inflammation: possible etiologic factors in the development of prostatic hyperplasia.
    Gleason PE; Jones JA; Regan JS; Salvas DB; Eble JN; Lamph WW; Vlahos CJ; Huang WL; Falcone JF; Hirsch KS
    J Urol; 1993 Jun; 149(6):1586-92. PubMed ID: 7684794
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lovastatin-induced apoptosis in prostate stromal cells.
    Padayatty SJ; Marcelli M; Shao TC; Cunningham GR
    J Clin Endocrinol Metab; 1997 May; 82(5):1434-9. PubMed ID: 9141529
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The histology of prostate tissue following prostatic artery embolization for the treatment of benign prostatic hyperplasia.
    Camara-Lopes G; Mattedi R; Antunes AA; Carnevale FC; Cerri GG; Srougi M; Alves VA; Leite KR
    Int Braz J Urol; 2013; 39(2):222-7. PubMed ID: 23683668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stromal cells of the human prostate: initial isolation and characterization.
    Kassen A; Sutkowski DM; Ahn H; Sensibar JA; Kozlowski JM; Lee C
    Prostate; 1996 Feb; 28(2):89-97. PubMed ID: 8604397
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Benign prostate hyperplasia and stem cells: a new therapeutic opportunity.
    Notara M; Ahmed A
    Cell Biol Toxicol; 2012 Dec; 28(6):435-42. PubMed ID: 23065175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.